Investor Relations

Corporate Overview

Corporate Overview

We are a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated companion diagnostic (CDx) and therapeutic (Rx) strategy that leverages our CELsignia CDx platform. CELsignia is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from targeted therapies. This enables a CELsignia CDx to support advancement of new indications for already approved targeted therapies. Our therapeutic strategy aims to utilize CELsignia’s unique insights into tumor cell biology to identify, in-license, and develop potential first-in-class or best-in-class targeted therapies that treat the same cancer driver a CELsignia CDx can identify. We believe this integrated CDx and Rx strategy will maximize the impact our CELsignia platform has on the treatment landscape for cancer patients.

We are a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic (Rx) and companion diagnostic (CDx) strategy that leverages our CELsignia CDx platform. Our therapeutic strategy aims to utilize CELsignia’s unique insights into tumor cell biology to develop potential first-in-class or best-in-class targeted therapies that treat the same cancer driver a CELsignia CDx can identify.  Our CELsignia CDx platform supports advancement of new indications for already approved targeted therapies.

Celcuity Inc. is a publicly listed (NASDAQ: CELC) clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy.  Our mission is to extend the lives of cancer patients by leveraging our proprietary CELsignia platform to develop first-in-class therapies and companion diagnostics. 

Celcuity’s lead therapeutic candidate, gedatolisib, is a potential first-in-class pan-PI3K and mTOR inhibitor. Celcuity is currently planning to initiate a Phase 3 registration-enabling clinical trial to evaluate gedatolisib as a potential first-in-class treatment for patients with ER+/HER2-negative metastatic breast cancer.  Our CELsignia companion diagnostics are currently being evaluated in five clinical trials to assess whether breast cancer patients identified with a CELsignia test respond to a matching targeted therapy.

Data Provided by Quotemedia with delay

STOCK
INFORMATION

NASDAQ: CELC

Press Releases

Press Releases

Upcoming Events

There are currently no events to display.

Corporate Presentation